R&DWe are opening a new era
in the global new drug development.

Pipelines

NCEs

NCEs
Indication Research Preclinical Phase I Phase II Phase III
CKD-732* Prader Willi Syndrome
- Aminopeptidase 2 inhibitor
- Inhibition of Adipogenesis by targeting angiogenesis
CKD-732* Severe Obesity
- Aminopeptidase 2 inhibitor
- Inhibition of Adipogenesis by targeting angiogenesis
CKD-732* Damaged
Hypothalamus obesity
- Aminopeptidase 2 inhibitor
- Inhibition of Adipogenesis by targeting angiogenesis
CKD-943** Pain, Uremic pruritus
- Opioid Receptor Kappa agonist
- No CNS related adverse events (affects PNS only)
CKD-516 Colorectal cancer
- Tublin Polymerization inhibitor
(vascular disrupting agent)
CKD-581 Multiple myeloma
- Pan-HDAC inhibitor
CKD-519 Dyslipidemia
- CETP inhibitor
CKD-506 Autoimmune disease
- HDAC6 inhibitor
CKD-504 Huntington’s disease
- HDAC6 inhibitor
CKD-508 Dyslipidemia
- CETP inhibitor
CKD-509 Cancer
- HDAC6 inhibitor

* CKD-732 : License-out to Zafgen(US)

** CKD-943 : License-in from Cara Therapeutics in the US

Biologics

Biologics
Indication Research Preclinical Phase I Phase II Phase III
CKD-11101 Anemia(Domestic)
- NESP Biosimilar (2nd generation of EPO)
CKD-11101 Anemia(Overseas)
- NESP/ARANESP Biosimilar (2nd generation of EPO)
CKD-12101 Neutropenia
- 2nd generation G-CSF
CKD-701 AMD
- Lucentis Biosimilar
CKD-702 Cancer
- Bispecific antibody

IMDs

IMDs
Indication Research Preclinical Phase I Phase II Phase III
CKD-337 Dyslipidemia
CKD-391 Dyslipidemia
CKD-330 ARB/CCB
CKD-395 Diabetes
CKD-390 Antivirus
CKD-841 Cancer
- Sustained release injection

Botanical Drugs

Botanical Drugs
Indication Research Preclinical Phase I Phase II Phase III
CKD-497 Expectorant
CKD-495 Gastric Ulcer